VAP-1 Inhibitors - Pipeline Insight, 2022

“VAP-1 Inhibitors- Pipeline Insight, 2022” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs based on VAP-1 Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

VAP-1 Inhibitors Understanding

VAP-1 Inhibitors: Overview

Vascular adhesion protein-1 (VAP-1) is an ectoenzyme that oxidates primary amines in a reaction producing also hydrogen peroxide. VAP-1 on the blood vessel endothelium regulates leukocyte extravasation from the blood into tissues under physiological and pathological conditions. Inhibition of VAP-1, also known as AOC3 protein inhibitors by neutralizing antibodies and by several novel small-molecule enzyme inhibitors interferes with leukocyte trafficking and alleviates inflammation in many experimental models. Targeting of VAP-1 also shows beneficial effects in several other diseases, such as ischemia/reperfusion, fibrosis, and cancer. Moreover, soluble VAP-1 levels may serve as a new prognostic biomarker in selected diseases.

VAP-1 Inhibitors Emerging Drugs Chapters

This segment of the VAP-1 Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

VAP-1 Inhibitors Emerging Drugs
• TERN-201: Terns Pharmaceuticals

TERN-201 is a potent SSAO inhibitor which provides an additional treatment mechanism for NASH by reducing oxidative stress and recruitment of white blood cells to the liver. TERN-201 is highly specific for SSAO, with a preferential in vitro selectivity index to SSAO over off-target monoamine oxidases (MAO) of >7,000-fold. Certain MAOs could be associated with potential drug-drug interactions in the NASH patient population. It is in phase I stage of development.
• PRX 167700: Proximagen

PRX167700 is a vascular adhesion protein-1 (VAP-1; AOC3) antagonist that is being developed by Proximagen (a subsidiary of BenevolentAI) for the treatment for Inflammatory pain. It is currently in phase II stage of development.
• TT-01025: TransThera Biosciences

TT-01025 is a novel inhibitor of Semicarbazide-Sensitive Amine Oxidase/Vascular Adhesion Protein-1 (SSAO/VAP-1) for NASH. LG Chem Life Sciences and TransThera Biosciences jointly announced the Investigational New Drug (IND) application of TT-01025 has been submitted to Food and Drug Administration (FDA) in the United States.

Further product details are provided in the report……..

VAP-1 Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different VAP-1 Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in VAP-1 Inhibitors

There are approx. 15+ key companies which are developing the therapies based on VAP-1 Inhibitors. The companies which have their drug candidate based on VAP-1 Inhibitors in the most advanced stage, i.e. phase II include Proximagen and others
• Phases

DelveInsight’s report covers around 15+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage products (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

VAP-1 Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Oral
• Parenteral
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Gene therapies
• Small molecule
• Vaccines
• Polymers
• Peptides
• Monoclonal antibodies
• Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

VAP-1 Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses VAP-1 Inhibitors therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging VAP-1 Inhibitors drugs.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence VAP-1 Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
• In September 2020, Terns Pharmaceuticals announced that TERN-201, a semicarbazide-sensitive amine oxidase (SSAO) inhibitor, has been granted Fast Track designation by the US Food and Drug Administration (FDA) for the treatment of non-alcoholic steatohepatitis (NASH).
• LG Chem reached an exclusive license agreement with TransThera Biosciences on August 2020 to research, develop, manufacture and commercialize TT-01025 in global region except Greater China and Japan.

VAP-1 Inhibitors Report Insights
• VAP-1 Inhibitors Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

VAP-1 Inhibitors Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
• What are the current treatment options available based on the VAP-1 Inhibitors?
• How many companies are developing therapies by working on VAP-1 Inhibitors?
• What are the principal therapies developed by these companies in the industry?
• How many therapies are developed by each company for VAP-1 Inhibitors to treat disease condition?
• How many emerging therapies are in early-stage, mid-stage, and late stage of development for VAP-1 Inhibitors?
• Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other treatments?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the VAP-1 Inhibitors therapies?
• Which are the dormant and discontinued products and the reasons for the same?
• What is the unmet need for current therapies developed based on this mechanism of action?
• What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for VAP-1 Inhibitors and their status?
• What are the results of the clinical studies and their safety and efficacy?
• What are the key designations that have been granted for the emerging therapies for VAP-1 Inhibitors?
• How many patents are granted and pending for the emerging therapies of VAP-1 Inhibitors?

Key Players
• Terns Pharmaceuticals
• Proximagen
• TransThera Biosciences
• Pharmaxis
• Acorda Therapeutics
• R-Tech Ueno
• Pharmaxis

Key Products
• TT-01025
• PRX 167700
• TERN-201
• Research programme: SSAO/VAP-1 protein inhibitors
• Research programme: VAP-1 SSAO enzyme inhibitors
• RTU 1096
• BI 1467335